Comprehensive assessment of immunity and approaches to differentiated immunocorrection in recurrent miscarriage

With the view of comprehensive assessment of immunity in 75 female patients having recurrent pregnancy loss in the past medical history, profiles of lymphocyte subpopulations from peripheral blood and endometrium were investigated. Depending on CD16+ levels in peripheral blood, female patients were divided into two groups: 43 females with low (first group) and 32 with high CD16+ levels (second group). It was found that the patients with high level of CD16+ lymphocytes had significantly higher levels of expression of the activation markers HLA-DR+ and CD95+ than those in the control group, and CD25+ expression levels were also higher compared to the first group. As a criterion for choosing the type of immunotherapy, CD95+/CD16+ index is used. If its value is less than 0.8 in the context of decrease of CD3+, CD4+, interferon inductors are prescribed, in case the index value is within the range of 0.9–1.29, interferon preparations are expedient. If the index value exceeds 1.3, interleukin-2 preparations are to be administered.